



## ATTACHMENT A

### Amendment to the Claims

*This listing of claims will replace all prior versions, and listings, of claims in the application:*

1-16. (Canceled)

17. (Currently amended) A method of preventing or modulating a T cell-mediated response in a host comprising administering to the host an isolated *S. aureus* Map protein having an amino acid sequence as set forth in ~~according to~~ SEQ ID NO:2 in an amount effective to prevent or modulate said T cell-mediated response in the host.

18. (Previously presented) The method according to Claim 17 wherein the T cell-mediated response is delayed-type hypersensitivity (DTH).

19. (Currently amended) A method of treating or preventing a pathological condition associated with overstimulation of T cells in a human or animal patient comprising administering to the ~~host~~patient an isolated *S. aureus* Map protein having an amino acid sequence according to SEQ ID NO:2 in an amount effective to treat or prevent said condition associated with overstimulation of T cells.

20. (Currently amended) TheA method according to Claim 19 wherein the condition associated with overstimulation of T cells is toxic shock syndrome.

21. (Currently amended) A method of treating or preventing a T cell lymphoproliferative disease in a human or animal patient comprising administering to the ~~host~~patient an isolated *S. aureus* Map protein having the~~an~~ amino acid sequence according to SEQ ID NO:2, in an amount effective to treat or prevent a T cell lymphoproliferative disease.